The expression of programmed death-ligand 1 (PD-L1) can be used as a clinical biomarker to determine the efficacy of immune checkpoint inhibitor treatment; however, there are many areas of uncertainty when it comes to PD-L1 testing. In this interview, recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, discusses the challenges of using PD-L1 levels as a determining factor in offering treatment to cancer patients.
- The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response ( Download)
- Immunotherapy in Oncology and the Role of the PD-L1 Biomarker ( Download)
- Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer ( Download)
- Expert Discusses the Role of PD-L1 Expression as a Predictive Biomarker in Urothelial Carcinoma ( Download)
- New biomarkers for response to immunotherapy ( Download)
- Dr. Mason on the Reliability of the PD-L1 Biomarker ( Download)
- The role of PD L1 in the immune dysfunction that mediates hypoxia induced multiple organ injury ( Download)
- Blood-based biomarkers for immunotherapy in NSCLC ( Download)
- Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment ( Download)
- Biomarkers in Cancer Immunotherapy: How Much Do They Matter ( Download)
- Pharmacist's advice on biomarkers for immunotherapy ( Download)
- Exploring the Role of Biomarkers in Patient Selection for Immunotherapy in Bladder Cancer ( Download)
- Nondriver NSCLC: Immunotherapy and PD-L1 Expression ( Download)
- Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies ( Download)
- Management of patients with PDL1-high advanced NSCLC ( Download)
